Editorials
Louis M. Weiner, MD,
Vice President, Translational Research and Chairman, Department of Medical Oncology, Fox Chase Cancer Center,
Philadelphia, Pennsylvania

Edward Chu, MD, Professor of Medicine and Pharmacology Director, VA CT Cancer Center, Associate Director, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut

Targeted Therapies: Multiple
Directions, New Insights
Roy Herbst, MD, Chief, Section of Thoracic Medical Oncology,
M. D. Anderson Cancer Center, Houston, Texas

Targeting the Epidermal Growth Factor Pathway in Targeted Therapy
Leonard B. Saltz, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center,
New York, New York

Cetuximab: Clinical Results in Head and Neck, Lung, and Pancreatic Cancers
Howard Hochster, MD, Associate Professor of Medicine, New York University School of Medicine,
New York, New York

Tyrosine Kinase Inhibitors: Current Evidence of
Clinical Activity
Roy Herbst, MD, Chief, Section of Thoracic Medical Oncology,
M. D. Anderson Cancer Center, Houston, Texas

Signaling Pathways as
Anti-Tumor Targets: COX-2,
RAS Kinase
Alan Sandler, MD, Vanderbilt University Medical Center, Nashville, Tennessee

Chemotherapy as a Targeted Treatment: Agents with Anti-Tumor Growth Effects
Kenneth B. Ain, MD, Division of Endocrinology and Molecular Medicine University of Kentucky School of Medicine, Lexington, Kentucky